Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
Holding CERS?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.01Last Year’s EPS
-$0.01Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: -8.14%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarterly performance with positive trends in revenue growth and business expansion, particularly in the North American market and the INTERCEPT Fibrinogen Complex business. However, challenges such as a decline in government contract revenue and regulatory hurdles in Europe were noted. Overall, the positive aspects significantly outweigh the negatives, indicating a positive outlook.Company Guidance
During the Cerus Corporation Q3 2024 earnings call, the company provided updated guidance reflecting strong quarterly performance and a positive outlook for the remainder of the year. Cerus raised its full-year 2024 product revenue guidance to a range of $177 million to $179 million, up from the prior range of $175 million to $178 million. The guidance was bolstered by notable growth in the North American platelet business and momentum in the U.S. INTERCEPT Fibrinogen Complex (IFC) segment, with third-quarter product revenue reaching $46 million, a 16% year-over-year increase. The company also adjusted its IFC revenue guidance to a range of $9 million to $10 million, acknowledging increasing demand and the issuance of three new Biologics License Application (BLA) approvals that enable broader distribution. Additionally, Cerus highlighted its commitment to maintaining positive non-GAAP adjusted EBITDA for 2024, following a third-quarter adjusted EBITDA of $4.4 million, and emphasized its strategic focus on expanding product supply and leveraging its business model to meet growing customer demand.Strong Quarterly Performance and Increased Revenue Guidance
Cerus Corporation reported strong performance in Q3 2024, with a product revenue of $46 million, representing a year-over-year growth of 16%. The company raised its full-year 2024 product revenue guidance to the range of $177 million to $179 million, up from the prior range of $175 million to $178 million.
Successful Expansion of INTERCEPT Fibrinogen Complex (IFC) Business
The INTERCEPT Fibrinogen Complex (IFC) business in the U.S. showed significant growth, with Q3 product revenue of $2.3 million, up from $1.7 million in the prior-year period. The company also reported three new BLA approvals, enabling broader interstate shipment of IFC.
Positive Adjusted EBITDA and Operating Cash Flows
Cerus reported a positive adjusted EBITDA of $4.4 million for Q3 2024, compared to a loss of nearly $1 million in the prior-year period. The company also generated positive operating cash flows of $4.1 million in Q3 2024, compared to cash used for operations of $10.5 million during Q3 2023.
New BARDA Contract and Regulatory Advancements
Cerus secured a new BARDA contract valued up to $248 million, designed to support the INTERCEPT RBC program through potential regulatory approval and product launch. The company is also progressing with regulatory submissions for its LED illuminator in Europe.
---
CERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $1.72 | $1.57 | -8.72% |
| Aug 01, 2024 | $2.04 | $2.34 | +14.71% |
| May 02, 2024 | $1.76 | $1.62 | -7.95% |
| Mar 05, 2024 | $1.99 | $2.42 | +21.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cerus Corp (CERS) report earnings?
Cerus Corp (CERS) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Cerus Corp (CERS) earnings time?
Cerus Corp (CERS) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERS EPS forecast?
CERS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.01.
---